In a regulatory filing made during market hours today, the company said that it had received ANDA approval for its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (US FDA). The product is a generic version of Celebrex capsules of G.D. Searle LLC, Division of Pfizer Inc.

Celecoxib capsules are indicated for treatment of osteoarthritis, rheumatoid arthritis juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain and primary dysmenorrhea.

The product will be commercialized from Unichem's Goa Plant,” the company said in a statement.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.

The company reported a consolidated net profit of Rs 8.74 crore in Q2 FY21 as compared to a net loss of Rs 22.21 crore in Q2 FY20. Net sales during the quarter jumped 18.4% YoY to Rs 317.51 crore.

Powered by Capital Market - Live News

Unichem Laboratories announced that ICRA has reaffirmed the long term rating on the Rs 146 crore bank facilities of the company to ICRA A. The outlook on the long term rating has been revised to Stable from Negative.

Powered by Capital Market - Live News

Unichem Laboratories announced that it has received ANDA approval for its Atenolol and Chlorthalidone Tablets, USP 50 mg/25 mg and 100 mg/25 mg from the United States Food and Drug Administration (USFDA) to market a generic version of TENORETIC® (atenolol and chlorthalidone) Tablets of Alvogen Malta Operations.

Atenolol and Chlorthalidone Tablets are indicated for the treatment of hypertension, to lower blood pressure. The product will be commercialized from Unichem's Ghaziabad Plant.

Powered by Capital Market - Live News

Net profit of Unichem Laboratories reported to Rs 8.74 crore in the quarter ended September 2020 as against net loss of Rs 22.21 crore during the previous quarter ended September 2019. Sales rose 18.41% to Rs 317.51 crore in the quarter ended September 2020 as against Rs 268.14 crore during the previous quarter ended September 2019.

Powered by Capital Market - Live News